H

Hospital General Universitario de Alicante | Neurology Department

Research site
(Unclaimed)
Location
Street Pintor Baeza 12, Alicante, Alicante, Spain
Site insights

Top conditions

Breast Cancer (27 trials)

Lung Cancer (18 trials)

Non-Small-Cell Lung Carcinoma (17 trials)

Atopic Dermatitis (12 trials)

Eczema (12 trials)

Top treatments

Emtricitabine
Trastuzumab
Etrasimod
Carboplatin
Atezolizumab
Adalimumab
Paclitaxel
Ruxolitinib
Cyclophosphamide
/Lamivudine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

46 of 232
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

This is a multicenter, prospective, non-randomized, Phase I-II trial to assess the efficacy and safety of the combination of oral quizartinib and FLA...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Idarubicin
Drug: Quizartinib

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Drug: Matching Placebo

The co-primary objectives of the study are to:Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Invest...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines...

Enrolling
Melanoma
Drug: encorafenib
Drug: ipilimumab

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Baricitinib
Drug: Placebo

Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots ca...

Enrolling
Thrombotic Thrombocytopenic Purpura (TTP)
Biological: Standard of care
Biological: BAX930

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelod...

Active, not recruiting
Higher Risk Myelodysplastic Syndromes
Drug: evorpacept
Drug: azacitidine

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Letrozole
Drug: Tamoxifen

The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative...

Active, not recruiting
Colitis, Ulcerative
Crohn's Disease
Drug: Vedolizumab SC

The main aim of the study is to check effectiveness of rVWF (vonicog alfa) prophylaxis based on the annualized bleeding rate (ABR) of spontaneous (no...

Enrolling
Von Willebrand Disease (VWD)
Biological: rVWF
Biological: rFVIII

The main aim of the study is to check effectiveness, side effects, and tolerability of recombinant von Willebrand Factor (rVWF), with or without ADVA...

Enrolling
Von Willebrand Disease
Biological: Antihemophilic Factor (Recombinant)
Biological: von Willebrand factor (Recombinant)

The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearr...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Cisplatin
Drug: Pemetrexed

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participa...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Tiragolumab
Drug: Atezolizumab

This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patie...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Atezolizumab
Drug: Tiragolumab

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting
HER2-Positive Primary Breast Cancer
Residual Invasive Breast Cancer
Drug: DS-8201a
Drug: T-DM1

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BI 1015550
Locations recently updated

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: Placebo
Drug: BI 1015550

This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammator...

Enrolling
Dermatomyositis
Myositis
Other: PBO
Biological: EFG PH20 SC

Trial sponsors

Pfizer logo

Pfizer (14 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems